ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1096

Usefulness of Multiplex Immunodot Method for COVID-19 Vaccination Monitoring in Dialysis Patients: Results of the COVIDIAL Study

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Debelle, Frederic, Centre Hospitalier EpiCURA Baudour, Baudour, Hainaut , Belgium
  • Gankam Kengne, Fabrice, Centre Hospitalier EpiCURA Ath, Ath, Hainaut , Belgium
  • Guillen-Anaya, Miguel-Ange, Centre Hospitalier EpiCURA Hornu, Hornu, Hainaut , Belgium
  • Decleves, Anne-Emilie, Universite de Mons, Mons, Walloon Region, Belgium

Group or Team Name

  • CoviDial Study Group.

COVID-19 vaccine was demonstrated to be effective in dialysis patients, but boosters are mandatory due to a rapid waning of anti-spike antibodies. A vaccination strategy based on efficient immunologic response monitoring might be useful to maintain a favourable risk-benefit balance in this vulnerable population.


CoviDial is an observational prospective study enrolling 121 dialysis patients to receive a 3-dose mRNA-1273 vaccine according to a uniform schedule. At baseline, months 1, 3, 6, 9, and 12, anti-spike antibodies against four epitopes (S1, S2, ECD-S1+S2, RBD) were monitored with a multiplex immunodot enzymatic assay. Potential correlation between initial serologic response and subsequent COVID-19 infection was then assessed.


Overall, 96.2% and 96.8% of patients developed anti-RBD antibodies at 3 and 12 months, respectively. All antibodies titres significantly decreased at month 6 compared to month 3. Booster vaccine induced a robust serologic response at month 9, but with a waning three months later, particularly for anti-S2 (37.2 ± 3.3 vs. 61.3 ± 3.0, p<0.0001) and anti-S1+S2 antibodies (68.4 ± 3.3 vs. 88.4 ± 2.3, p<0.01). Fifteen patients were later tested positive for SARS-CoV-2. At month 3, mean titres of anti-RBD, anti-S1+S2 and anti-S2 antibodies were lower in the subsequent SARS-CoV-2 infected cohort (71.57±9.01 vs. 85.79±2.61, p<0.05; 41.07±7.96 vs. 61.68±3.56, p<0.05; 13.79±5.03 vs. 39.70±3.86, p<0.01; respectively).


Three doses of mRNA-1273 vaccine induce a robust but time-limited immunologic response in dialysis patients. Lower anti-spike antibodies titres after initial vaccination are associated with a higher risk to subsequently contract SARS-CoV-2, even beyond six months.


  • Private Foundation Support